Pharma Co. Faces Investor Suit Over $1.8B AstraZeneca Deal
An investor in biopharmaceutical company CinCor Pharma Inc. has alleged there were misrepresentations in a document that detailed a proposed acquisition of CinCor worth up to $1.8 billion by European pharmaceutical company AstraZeneca...To view the full article, register now.
Already a subscriber? Click here to view full article